BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

403 related articles for article (PubMed ID: 33466691)

  • 1. Cancer Vaccines, Treatment of the Future: With Emphasis on HER2-Positive Breast Cancer.
    Pallerla S; Abdul AURM; Comeau J; Jois S
    Int J Mol Sci; 2021 Jan; 22(2):. PubMed ID: 33466691
    [TBL] [Abstract][Full Text] [Related]  

  • 2. HER2-Positive Breast Cancer Immunotherapy: A Focus on Vaccine Development.
    Arab A; Yazdian-Robati R; Behravan J
    Arch Immunol Ther Exp (Warsz); 2020 Jan; 68(1):2. PubMed ID: 31915932
    [TBL] [Abstract][Full Text] [Related]  

  • 3. HER2-Based Immunotherapy for Breast Cancer.
    Cui N; Shi J; Yang C
    Cancer Biother Radiopharm; 2018 Jun; 33(5):169-175. PubMed ID: 29874101
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Breast Cancer Vaccines: Disappointing or Promising?
    Zhu SY; Yu KD
    Front Immunol; 2022; 13():828386. PubMed ID: 35154149
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Developing anti-HER2 vaccines: Breast cancer experience.
    Al-Awadhi A; Lee Murray J; Ibrahim NK
    Int J Cancer; 2018 Nov; 143(9):2126-2132. PubMed ID: 29693245
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Vaccination for the prevention and treatment of breast cancer with special focus on Her-2/neu peptide vaccines.
    Wiedermann U; Davis AB; Zielinski CC
    Breast Cancer Res Treat; 2013 Feb; 138(1):1-12. PubMed ID: 23340862
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Anti-HER2 vaccines: The HER2 immunotargeting future?].
    Ladjemi MZ; Jacot W; Pèlegrin A; Navarro-Teulon I
    Pathol Biol (Paris); 2011 Jun; 59(3):173-82. PubMed ID: 19481373
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Progress in Vaccine Therapies for Breast Cancer.
    Li X; Bu X
    Adv Exp Med Biol; 2017; 1026():315-330. PubMed ID: 29282691
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Vaccine immunotherapy in breast cancer treatment: promising, but still early.
    Curigliano G; Spitaleri G; Dettori M; Locatelli M; Scarano E; Goldhirsch A
    Expert Rev Anticancer Ther; 2007 Sep; 7(9):1225-41. PubMed ID: 17892423
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Exosomal pMHC-I complex targets T cell-based vaccine to directly stimulate CTL responses leading to antitumor immunity in transgenic FVBneuN and HLA-A2/HER2 mice and eradicating trastuzumab-resistant tumor in athymic nude mice.
    Wang L; Xie Y; Ahmed KA; Ahmed S; Sami A; Chibbar R; Xu Q; Kane SE; Hao S; Mulligan SJ; Xiang J
    Breast Cancer Res Treat; 2013 Jul; 140(2):273-84. PubMed ID: 23881522
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Emerging Therapeutic Options for HER2-Positive Breast Cancer.
    Martin M; López-Tarruella S
    Am Soc Clin Oncol Educ Book; 2016; 35():e64-70. PubMed ID: 27249772
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Therapeutic breast cancer vaccines: a new strategy for early-stage disease.
    Shumway NM; Ibrahim N; Ponniah S; Peoples GE; Murray JL
    BioDrugs; 2009; 23(5):277-87. PubMed ID: 19754218
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Stimulation of Oncogene-Specific Tumor-Infiltrating T Cells through Combined Vaccine and αPD-1 Enable Sustained Antitumor Responses against Established HER2 Breast Cancer.
    Crosby EJ; Acharya CR; Haddad AF; Rabiola CA; Lei G; Wei JP; Yang XY; Wang T; Liu CX; Wagner KU; Muller WJ; Chodosh LA; Broadwater G; Hyslop T; Shepherd JH; Hollern DP; He X; Perou CM; Chai S; Ashby BK; Vincent BG; Snyder JC; Force J; Morse MA; Lyerly HK; Hartman ZC
    Clin Cancer Res; 2020 Sep; 26(17):4670-4681. PubMed ID: 32732224
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The clinical development of vaccines for HER2
    Costa RLB; Soliman H; Czerniecki BJ
    Cancer Treat Rev; 2017 Dec; 61():107-115. PubMed ID: 29125981
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Immunotherapy as a partner for HER2-directed therapies.
    Clifton GT; Peoples AGE
    Expert Rev Anticancer Ther; 2021 Jul; 21(7):739-746. PubMed ID: 33666116
    [No Abstract]   [Full Text] [Related]  

  • 16. Immunotherapy in breast cancer: Current status and future directions.
    Basu A; Ramamoorthi G; Jia Y; Faughn J; Wiener D; Awshah S; Kodumudi K; Czerniecki BJ
    Adv Cancer Res; 2019; 143():295-349. PubMed ID: 31202361
    [TBL] [Abstract][Full Text] [Related]  

  • 17. AE37: a HER2-targeted vaccine for the prevention of breast cancer recurrence.
    McCarthy PM; Clifton GT; Vreeland TJ; Adams AM; O'Shea AE; Peoples GE
    Expert Opin Investig Drugs; 2021 Jan; 30(1):5-11. PubMed ID: 33191799
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Breast cancer vaccines; A comprehensive and updated review.
    Al-Hawary SIS; Saleh EAM; Mamajanov NA; S Gilmanova N; Alsaab HO; Alghamdi A; Ansari SA; Alawady AHR; Alsaalamy AH; Ibrahim AJ
    Pathol Res Pract; 2023 Sep; 249():154735. PubMed ID: 37611432
    [TBL] [Abstract][Full Text] [Related]  

  • 19. DNA vaccines targeting the encoded antigens to dendritic cells induce potent antitumor immunity in mice.
    Cao J; Jin Y; Li W; Zhang B; He Y; Liu H; Xia N; Wei H; Yan J
    BMC Immunol; 2013 Aug; 14():39. PubMed ID: 23941509
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Synergism from combined immunologic and pharmacologic inhibition of HER2 in vivo.
    Morse MA; Wei J; Hartman Z; Xia W; Ren XR; Lei G; Barry WT; Osada T; Hobeika AC; Peplinski S; Jiang H; Devi GR; Chen W; Spector N; Amalfitano A; Lyerly HK; Clay TM
    Int J Cancer; 2010 Jun; 126(12):2893-903. PubMed ID: 19856307
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 21.